immutep (asx:imm) announces positive results in head and neck cancer treatment
Published 10 days ago • 44 plays • Length 8:42Download video MP4
Download video MP3
Similar videos
-
6:21
how immutep treats head & neck cancer
-
47:53
immutep (asx:imm) tacti-003 results, june 2024
-
15:49
immutep (asx:imm) - webinar presentation
-
12:28
clinical trials in cancer and autoimmune diseases: immutep's ceo marc voigt provides an update
-
10:01
encouraging results for immutep's cancer therapies
-
16:06
immutep (asx:imm) - webinar presentation
-
16:07
immutep (asx:imm) - webinar presentation
-
46:43
immutep (asx:bla) - tacti-003 positive data in patients with negative pd-l1 expression (cohort b)
-
5:10
immutep (asx:imm) reports first subject dosed in autoimmune disease study
-
4:40
immutep (asx:imm) announces encouraging trial data for lung cancer therapy
-
50:22
immutep (asx:imm) esmo congress results webinar, october 2023
-
7:17
immutep (asx:imm) delivering strong data in first-line non-small cell lung cancer
-
52:08
immutep (asx:imm) - update on tacti-002 phase ii and insight-003 phase 1 data presented at sitc 2022
-
0:21
immutep (asx:imm) receives positive feedback from fda
-
56:38
immutep (asx:imm, nasdaq:immp) webcast for tacti-002 data presented at asco 2022 - 10 jun 2022
-
1:14:06
immutep (asx:imm) sitc 2021 results - management update
-
7:58
immutep: a leader in a league alongside global pharma giants
-
3:33
immutep (asx:imm) reports positive trial data
-
4:44
immutep (asx:imm) - innovative cancer therapies